We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MabCure Launches Clinical Trial to Diagnose Ovarian Cancer
News

MabCure Launches Clinical Trial to Diagnose Ovarian Cancer

MabCure Launches Clinical Trial to Diagnose Ovarian Cancer
News

MabCure Launches Clinical Trial to Diagnose Ovarian Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MabCure Launches Clinical Trial to Diagnose Ovarian Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MabCure, N.V. (MabCure) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.

“MabCure’s proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well.”

Dr. Amnon Gonenne, MabCure’s President and CEO commented, “We are very excited about the commencement of this study. We have been working hard to establish key partnerships with respectable research institutions and hospitals in Europe and the Far East, and this is no exception. We are looking forward to the results of the study and to moving MabCure forward towards having our diagnostic products on the market.”

“We know our diagnostic products have the potential to save many lives, and our mission is to get them to market as quickly as possible,” Dr. Gonenne added.

“MabCure’s proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well,” said Dr. Gonenne.
Advertisement